Dynavax Technologies Co. (NASDAQ:DVAX) shares dropped 9.2% on Wednesday . The stock traded as low as $10.53 and last traded at $10.60. Approximately 1,165,325 shares changed hands during trading, an increase of 32% from the average daily volume of 885,809 shares. The stock had previously closed at $11.67.
DVAX has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Dynavax Technologies from a “sell” rating to a “hold” rating in a research report on Thursday, August 9th. BidaskClub cut Dynavax Technologies from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 18th. Cantor Fitzgerald restated a “buy” rating and issued a $30.00 price target on shares of Dynavax Technologies in a research report on Monday, October 1st. Royal Bank of Canada raised their price target on Dynavax Technologies to $26.00 and gave the stock an “outperform” rating in a research report on Monday, October 22nd. Finally, Cowen restated a “buy” rating and issued a $30.00 price target on shares of Dynavax Technologies in a research report on Monday, October 22nd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the stock. Dynavax Technologies presently has a consensus rating of “Hold” and an average price target of $28.00.
The company has a quick ratio of 5.90, a current ratio of 6.29 and a debt-to-equity ratio of 1.03. The stock has a market capitalization of $708.41 million, a P/E ratio of -6.13 and a beta of 0.46.
Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Monday, November 5th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.57) by ($0.08). Dynavax Technologies had a negative return on equity of 97.79% and a negative net margin of 5,044.85%. The company had revenue of $1.46 million during the quarter, compared to the consensus estimate of $3.16 million. During the same quarter in the previous year, the business posted ($0.38) EPS. The firm’s revenue for the quarter was up 2822.0% on a year-over-year basis. On average, equities analysts forecast that Dynavax Technologies Co. will post -2.51 earnings per share for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Quantbot Technologies LP bought a new position in shares of Dynavax Technologies in the third quarter worth $131,000. Pacer Advisors Inc. acquired a new stake in Dynavax Technologies in the third quarter valued at about $132,000. Gofen & Glossberg LLC IL acquired a new stake in Dynavax Technologies in the third quarter valued at about $145,000. Tiverton Asset Management LLC acquired a new stake in Dynavax Technologies in the second quarter valued at about $184,000. Finally, Bank of Montreal Can boosted its stake in Dynavax Technologies by 365.4% in the second quarter. Bank of Montreal Can now owns 13,938 shares of the biopharmaceutical company’s stock valued at $213,000 after buying an additional 10,943 shares in the last quarter. Institutional investors own 76.73% of the company’s stock.
WARNING: “Dynavax Technologies (DVAX) Trading Down 9.2%” was first reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.dispatchtribunal.com/2018/12/06/dynavax-technologies-dvax-trading-down-9-2.html.
Dynavax Technologies Company Profile (NASDAQ:DVAX)
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.
Recommended Story: Cost of equity and a company’s balance sheet
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.